Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial.

Olafson LR, Siddell AH, Field KM, Byrnes M, Rapkins RW, Ng B, Nixdorf S, Barnes EH, Johns TG, Yip S, Simes J, Nowak AK, Rosenthal MA, McDonald KL.

J Clin Neurosci. 2019 Sep 30. pii: S0967-5868(19)31182-8. doi: 10.1016/j.jocn.2019.08.044. [Epub ahead of print]

PMID:
31582283
2.

Simultaneous Targeting of DNA Replication and Homologous Recombination in Glioblastoma with a Polyether Ionophore.

Lim YC, Ensbey KS, Offenhäuser C, D'Souza RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli V, Mahboubi B, Smith F, Jeffree RL, Wiesmüeller L, Wiegmans AP, Bain A, Lombard FJ, Roberts TL, Khanna KK, Lavin MF, Baek K, Hamerlik P, Johns TG, Coster MJ, Boyd AW, Day BW.

Neuro Oncol. 2019 Aug 30. pii: noz159. doi: 10.1093/neuonc/noz159. [Epub ahead of print]

PMID:
31504812
3.

The dystroglycan receptor maintains glioma stem cells in the vascular niche.

Day BW, Lathia JD, Bruce ZC, D'Souza RCJ, Baumgartner U, Ensbey KS, Lim YC, Stringer BW, Akgül S, Offenhäuser C, Li Y, Jamieson PR, Smith FM, Jurd CLR, Robertson T, Inglis PL, Lwin Z, Jeffree RL, Johns TG, Bhat KPL, Rich JN, Campbell KP, Boyd AW.

Acta Neuropathol. 2019 Aug 28. doi: 10.1007/s00401-019-02069-x. [Epub ahead of print]

PMID:
31463571
4.

Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.

Greenall SA, McKenzie M, Seminova E, Dolezal O, Pearce L, Bentley J, Kuchibhotla M, Chen SC, McDonald KL, Kornblum H, Endersby R, Adams TE, Johns TG.

Neuro Oncol. 2019 Apr 19. pii: noz073. doi: 10.1093/neuonc/noz073. [Epub ahead of print]

PMID:
31002307
5.

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.

Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW.

Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z.

6.

Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.

Donoghue JF, Kerr LT, Alexander NW, Greenall SA, Longano AB, Gottardo NG, Wang R, Tabar V, Adams TE, Mischel PS, Johns TG.

Cancers (Basel). 2018 Jul 25;10(8). pii: E243. doi: 10.3390/cancers10080243.

7.

Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.

Hoque M, Abbassi RH, Froio D, Man J, Johns TG, Stringer BW, Day BW, Pajic M, Kassiou M, Munoz L.

Pharmacol Res. 2018 Aug;134:166-178. doi: 10.1016/j.phrs.2018.06.023. Epub 2018 Jun 23.

PMID:
29944980
8.

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000-10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial.

Skubisz MM, Tong S, Doust A, Mollison J, Johns TG, Neil P, Robinson M, Bhattacharya S, Wallace E, Krzys N, Colin Duncan W, Horne AW.

EBioMedicine. 2018 Jul;33:276-281. doi: 10.1016/j.ebiom.2018.06.017. Epub 2018 Jun 22.

9.

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3.

Greenall SA, Donoghue J, Johns TG, Adams TE.

Transl Oncol. 2018 Aug;11(4):971-978. doi: 10.1016/j.tranon.2018.05.011. Epub 2018 Jun 22.

10.

PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.

Daniel PM, Filiz G, Brown DV, Christie M, Waring PM, Zhang Y, Haynes JM, Pouton C, Flanagan D, Vincan E, Johns TG, Montgomery K, Phillips WA, Mantamadiotis T.

Neuro Oncol. 2018 Sep 3;20(10):1344-1355. doi: 10.1093/neuonc/noy068.

11.

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.

Endersby R, Whitehouse J, Hii H, Greenall SA, Johns TG, Gottardo NG.

Neoplasia. 2018 May;20(5):432-442. doi: 10.1016/j.neo.2018.02.004. Epub 2018 Mar 22.

12.

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.

Greenall SA, Lim YC, Mitchell CB, Ensbey KS, Stringer BW, Wilding AL, O'Neill GM, McDonald KL, Gough DJ, Day BW, Johns TG.

Oncogenesis. 2017 May 15;6(5):e336. doi: 10.1038/oncsis.2017.33.

13.

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.

Gilabert-Oriol R, Furness SGB, Stringer BW, Weng A, Fuchs H, Day BW, Kourakis A, Boyd AW, Hare DL, Thakur M, Johns TG, Wookey PJ.

Cancer Immunol Immunother. 2017 Sep;66(9):1217-1228. doi: 10.1007/s00262-017-2013-z. Epub 2017 May 13.

PMID:
28501939
14.

Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent.

Döbber A, Phoa AF, Abbassi RH, Stringer BW, Day BW, Johns TG, Abadleh M, Peifer C, Munoz L.

ACS Med Chem Lett. 2017 Mar 15;8(4):395-400. doi: 10.1021/acsmedchemlett.6b00483. eCollection 2017 Apr 13.

15.

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

Zhou Q, Phoa AF, Abbassi RH, Hoque M, Reekie TA, Font JS, Ryan RM, Stringer BW, Day BW, Johns TG, Munoz L, Kassiou M.

J Med Chem. 2017 Mar 9;60(5):2052-2070. doi: 10.1021/acs.jmedchem.6b01840. Epub 2017 Feb 28.

PMID:
28206758
16.

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma.

Kerr LT, Donoghue JF, Wilding AL, Johns TG.

Sarcoma. 2016;2016:3484673. Epub 2016 Oct 16.

17.

EGFRvIII: the promiscuous mutation.

Greenall SA, Johns TG.

Cell Death Discov. 2016 Jul 4;2:16049. doi: 10.1038/cddiscovery.2016.49. eCollection 2016. No abstract available.

18.

Mitochondrial DNA plasticity is an essential inducer of tumorigenesis.

Lee WT, Cain JE, Cuddihy A, Johnson J, Dickinson A, Yeung KY, Kumar B, Johns TG, Watkins DN, Spencer A, St John JC.

Cell Death Discov. 2016 Apr 4;2:16016. doi: 10.1038/cddiscovery.2016.16. eCollection 2016.

19.

Incomplete target neutralization by the anti-cancer antibody rilotumumab.

Greenall SA, Adams TE, Johns TG.

MAbs. 2016;8(2):246-52. doi: 10.1080/19420862.2015.1122149.

20.

Targeted drug delivery using genetically engineered diatom biosilica.

Delalat B, Sheppard VC, Rasi Ghaemi S, Rao S, Prestidge CA, McPhee G, Rogers ML, Donoghue JF, Pillay V, Johns TG, Kröger N, Voelcker NH.

Nat Commun. 2015 Nov 10;6:8791. doi: 10.1038/ncomms9791.

PMID:
26556723
21.

Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling.

Phoa AF, Browne S, Gurgis FM, Åkerfeldt MC, Döbber A, Renn C, Peifer C, Stringer BW, Day BW, Wong C, Chircop M, Johns TG, Kassiou M, Munoz L.

Biochem Pharmacol. 2015 Dec 15;98(4):587-601. doi: 10.1016/j.bcp.2015.10.014. Epub 2015 Oct 28.

PMID:
26519552
22.

Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.

Palmer KR, Kaitu'u-Lino TJ, Hastie R, Hannan NJ, Ye L, Binder N, Cannon P, Tuohey L, Johns TG, Shub A, Tong S.

Hypertension. 2015 Dec;66(6):1251-9. doi: 10.1161/HYPERTENSIONAHA.115.05883. Epub 2015 Sep 28.

PMID:
26416849
23.

Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines.

Rahman M, Reyner K, Deleyrolle L, Millette S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, Duggal R, Reynolds BA.

Anat Cell Biol. 2015 Mar;48(1):25-35. doi: 10.5115/acb.2015.48.1.25. Epub 2015 Mar 20.

24.

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.

Abbassi R, Johns TG, Kassiou M, Munoz L.

Pharmacol Ther. 2015 Jul;151:87-98. doi: 10.1016/j.pharmthera.2015.03.004. Epub 2015 Mar 17. Review.

PMID:
25795597
25.

Mitochondrial DNA copy number is regulated by DNA methylation and demethylation of POLGA in stem and cancer cells and their differentiated progeny.

Lee W, Johnson J, Gough DJ, Donoghue J, Cagnone GL, Vaghjiani V, Brown KA, Johns TG, St John JC.

Cell Death Dis. 2015 Feb 26;6:e1664. doi: 10.1038/cddis.2015.34.

26.

EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.

Greenall SA, Donoghue JF, Van Sinderen M, Dubljevic V, Budiman S, Devlin M, Street I, Adams TE, Johns TG.

Oncogene. 2015 Oct 8;34(41):5277-87. doi: 10.1038/onc.2014.448. Epub 2015 Feb 9.

PMID:
25659577
27.

Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2.

Gurgis F, Åkerfeldt MC, Heng B, Wong C, Adams S, Guillemin GJ, Johns TG, Chircop M, Munoz L.

Cell Death Discov. 2015 Sep 7;1:15028. doi: 10.1038/cddiscovery.2015.28. eCollection 2015.

28.

Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.

Ciprotti M, Chong G, Gan HK, Chan A, Murone C, MacGregor D, Lee FT, Johns TG, Heath JK, Ernst M, Burgess AW, Scott AM.

EJNMMI Res. 2014 May 30;4:22. doi: 10.1186/s13550-014-0022-x. eCollection 2014.

29.

Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: a case series.

Horne AW, Skubisz MM, Tong S, Duncan WC, Neil P, Wallace EM, Johns TG.

Hum Reprod. 2014 Jul;29(7):1375-9. Epub 2014 May 7.

30.

Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.

Greenall SA, Donoghue JF, Gottardo NG, Johns TG, Adams TE.

Oncogene. 2015 Mar 26;34(13):1658-66. doi: 10.1038/onc.2014.106. Epub 2014 Apr 21.

PMID:
24747966
31.

The identification of mitochondrial DNA variants in glioblastoma multiforme.

Yeung KY, Dickinson A, Donoghue JF, Polekhina G, White SJ, Grammatopoulos DK, McKenzie M, Johns TG, St John JC.

Acta Neuropathol Commun. 2014 Jan 2;2:1. doi: 10.1186/2051-5960-2-1.

32.

Glioma surgical aspirate: a viable source of tumor tissue for experimental research.

Day BW, Stringer BW, Wilson J, Jeffree RL, Jamieson PR, Ensbey KS, Bruce ZC, Inglis P, Allan S, Winter C, Tollesson G, Campbell S, Lucas P, Findlay W, Kadrian D, Johnson D, Robertson T, Johns TG, Bartlett PF, Osborne GW, Boyd AW.

Cancers (Basel). 2013 Apr 3;5(2):357-71. doi: 10.3390/cancers5020357.

33.

Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy.

Skubisz MM, Horne AW, Johns TG, Nilsson UW, Duncan WC, Wallace EM, Critchley HO, Tong S.

Obstet Gynecol. 2013 Oct;122(4):745-51. doi: 10.1097/AOG.0b013e3182a14cfb.

PMID:
24084530
34.

Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.

Nilsson UW, Johns TG, Wilmann T, Kaitu'u-Lino T, Whitehead C, Dimitriadis E, Menkhorst E, Saglam B, Gao Y, Greenall SA, Horne AW, Tong S.

Obstet Gynecol. 2013 Oct;122(4):737-44. doi: 10.1097/AOG.0b013e3182a1ba56.

PMID:
24084529
35.

The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma.

Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C, McDonald KL.

Tumour Biol. 2014 Feb;35(2):1459-65. doi: 10.1007/s13277-013-1200-6. Epub 2013 Sep 26.

PMID:
24068568
36.

The regulation of mitochondrial DNA copy number in glioblastoma cells.

Dickinson A, Yeung KY, Donoghue J, Baker MJ, Kelly RD, McKenzie M, Johns TG, St John JC.

Cell Death Differ. 2013 Dec;20(12):1644-53. doi: 10.1038/cdd.2013.115. Epub 2013 Aug 30.

37.

Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts.

Lee ST, Ji H, Greening DW, Speirs RW, Rigopoulos A, Pillay V, Murone C, Vitali A, Stühler K, Johns TG, Corner GA, Mariadason JM, Simpson RJ, Scott AM.

Growth Factors. 2013 Oct;31(5):154-64. doi: 10.3109/08977194.2013.824435. Epub 2013 Aug 20.

PMID:
23957735
38.

Targeting the ERBB family in cancer: couples therapy.

Tebbutt N, Pedersen MW, Johns TG.

Nat Rev Cancer. 2013 Sep;13(9):663-73. doi: 10.1038/nrc3559. Epub 2013 Aug 16. Review.

PMID:
23949426
39.

Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol.

Horne AW, Skubisz MM, Doust A, Duncan WC, Wallace E, Critchley HO, Johns TG, Norman JE, Bhattacharya S, Mollison J, Rassmusen M, Tong S.

BMJ Open. 2013 Jul 19;3(7). pii: e002902. doi: 10.1136/bmjopen-2013-002902. Print 2013.

40.

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.

Gan HK, Cvrljevic AN, Johns TG.

FEBS J. 2013 Nov;280(21):5350-70. doi: 10.1111/febs.12393. Epub 2013 Jul 8. Review.

41.

Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs.

Secret E, Smith K, Dubljevic V, Moore E, Macardle P, Delalat B, Rogers ML, Johns TG, Durand JO, Cunin F, Voelcker NH.

Adv Healthc Mater. 2013 May;2(5):718-27. doi: 10.1002/adhm.201200335. Epub 2012 Nov 30.

PMID:
23203914
42.

A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation.

Koziolek EJ, Donoghue JF, Bentley JD, Lovrecz G, Dolezal O, Ward CW, Rothacker J, Nice EC, Burgess AW, Hafner M, Johns TG, Adams TE.

Growth Factors. 2012 Oct;30(5):310-9. Epub 2012 Aug 2.

PMID:
22856597
43.

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG.

PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12.

44.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.

Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.

J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12.

PMID:
22412142
45.

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.

Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee WK, Cheng SY.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3018-23. doi: 10.1073/pnas.1121457109. Epub 2012 Feb 7.

46.

A simple guide screw method for intracranial xenograft studies in mice.

Donoghue JF, Bogler O, Johns TG.

J Vis Exp. 2011 Sep 26;(55). pii: 3157. doi: 10.3791/3157.

47.

Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.

Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG.

J Cell Sci. 2011 Sep 1;124(Pt 17):2938-50. doi: 10.1242/jcs.083295.

48.

Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.

Ymer SI, Greenall SA, Cvrljevic A, Cao DX, Donoghue JF, Epa VC, Scott AM, Adams TE, Johns TG.

Cancers (Basel). 2011 Apr 18;3(2):2032-49. doi: 10.3390/cancers3022032.

49.

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F.

Genes Dev. 2010 Aug 15;24(16):1731-45. doi: 10.1101/gad.1890510.

50.

MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.

Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE, Scott AM.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):572-8. doi: 10.1016/j.ijrobp.2010.03.027. Epub 2010 Jul 16.

PMID:
20638193

Supplemental Content

Loading ...
Support Center